1 / 15

Medical Abbrevation

Medical Abbrevation. Nantawarn Kitikannakorn, B.Pharm,Pharm.D. Abbreviation Advantages. Convenience Time saver Space saver a way of avoiding the possibility of misspelling words. Abbreviation Disadvantages. Hard to understand Misread interpreted incorrectly

isla
Télécharger la présentation

Medical Abbrevation

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Medical Abbrevation Nantawarn Kitikannakorn, B.Pharm,Pharm.D

  2. AbbreviationAdvantages • Convenience • Time saver • Space saver • a way of avoiding the possibility of misspelling words

  3. AbbreviationDisadvantages • Hard to understand • Misread • interpreted incorrectly • Lengthen time needed to train individuals in the health field • Waste time to tracking down their meaning • Time’s delay patient care • Occasionally results in patient harm

  4. Dangerous abbrevation

  5. Easily misread Abbreviation

  6. Ambiguous meanings

  7. Controlled vocabulatory

  8. Controlled vocabulatory

  9. Prescription must be specified... • Dosage form • Strength • Direction • Indication

  10. Glasgow coma scale* MVE * References : Leaderman RJ.The internal Medicine& critical care pocket book. California: Tarascon publishing; 1997.

  11. Folstein Mini-Mental State* Score : 0-23 suggestscognitive dysfunction, 23-29 altered mental status

  12. Staging breast cancer * References : Leaderman RJ.The internal Medicine& critical care pocket book. California: Tarascon publishing; 1997.

  13. Staging ovarian cancer Retroperitoneal or inguinal node involvement Distant metastasis, pleural effusion must contain malignant cells 5 0%

  14. Staging prostate cancer

  15. Staging of lung cancer • TX malignant cell found but not visualized radiographically or bronchoscopically • T0 No evidence of primary tumor • Tis Carcinoma in situ • T1 Tumor < 3 cm surrounded by lung or viseral pleura, without invidence of invasion proximal to a lobar bronchus • T2 Tumor > 3 cm or either invades pleura or obstructive pneumonitis extending to the hilar region • T3 Tumor of any size with direct extension to the chest wall • T4 Worse than T3 or malignant pleural effusion • N0 No demonstrable metastases to regional nodes • N1 Mets to peribronchial including direct extension • N2 Mets to ipsilateral mediastinal and subcranial • N3 Mets to contralateral mediastinal, contralateral hilar, ipsilateral or contralateral scalenece or supracravicular • MO no known distant metastases • M1 Distant metastasis present

More Related